

With patronage of



SIE
Società Italiana di Ematologia

Current Challenges in Hematology – 1st edition

Rome, 25-26 January 2023
NH ROMA CENTRO Roma

PRESIDENT
Alessandro Isidori

HONORARY PRESIDENTS
Giuseppe Visani
Giovanni Martinelli

DAY 1

January 25th 2023

09.00 Congress open
Alessandro Isidori

09.15 Lecture – Current treatment strategies in multiple myeloma
Maria Victoria Mateos • Salamanca

09.15 SESSION I

CHALLENGES IN MULTIPLE MYELOMA
Chairmen: Maria Victoria Mateos, Giuseppe Visani

09.45 How to define high-risk myeloma according to new prognostic factors
Francesca Gay • Torino

10.05 Patient journey for a transplant-eligible patient from first line to subsequent lines
Elena Zamagni • Bologna

10.25 Patient journey for a transplant-ineligible patient from first line to subsequent lines
Roberto Mina • Torino

10.45 Efficacy of therapies involving BCMA-Targeted Therapies in Pretreated Patients with relapsed/refractory MM
Claudio Cerchione • Meldola

11.10 Discussion

11.20 Coffee Break

11.50 SESSION II

CHALLENGES IN LYMPHOMAS
Chairmen: Guido Gini, Umberto Vitolo

11.50 Unmet needs in mantle cell lymphoma
Carlo Visco • Verona

12.10 What's new in Waldenström Macroglobulinemia
Alessandra Tedeschi • Milano

12.30 Patient's journey for DLBCL not eligible for transplant
Guido Gini • Ancona

12.50 CAR-T in lymphomas: state of the art
Maurizio Martelli • Rome

13.10 Bispecific antibodies for B cell lymphomas
Umberto Vitolo • Candiolo

13.30 Light lunch

14.30 SESSION III

CHALLENGES IN CHRONIC LYMPHOCYTIC LEUKEMIA

Chairmen: Francesca Romana Mauro, Antonio Cuneo

14.30 Emerging prognostic-predictive factors
Antonio Cuneo • Ferrara

14.50 Why choosing front-line fixed-duration therapy
Othman al Sawaf • Cologne

15.10 Why choosing front-line continuous therapy
Francesca Romana Mauro • Roma

15.30 Sequencing in CLL
Lydia Scarfò • Milano

15.50 Discussion

16.00 SESSION IV

CHALLENGES IN CHRONIC MYELOID LEUKEMIA

Chairmen: Giuseppe Saglio, Gianantonio Rosti

16.00 How I treat advanced phase CML
Giuseppe Saglio • Torino

16.20 What's new beyond first line treatment: ponatinib
Gianantonio Rosti • Meldola

16.40 What's new beyond first line treatment: asciminib
Massimo Breccia • Rome

17.00 Discussion

17.20 SESSION V

CHALLENGES IN ACUTE LYMPHOBLASTIC LEUKEMIA

Chairmen: Giovanni Martinelli, Sabina Chiaretti

17.20 New treatment strategies for Ph-like ALL
Sabina Chiaretti • Rome

17.40 New treatment strategies for Ph-negative ALL
Nikola Goekbuget • Frankfurt

18.00 CAR-T in childhood ALL: history of a revolution
Franco Locatelli • Rome

18.10 Discussion

18.20 Day-1 closing

DAY 2

January 26th 2023

09.00 - 10.00
Sponsored Symposium with educational contribution by Servier
EXTRA ECM

ACUTE MYELOID LEUKEMIA: HOW DO CANCER GENOMICS GUIDE THERAPEUTIC CHOICES

Chairman: Alessandro Isidori

The Importance of Molecular Testing
Maria Teresa Voso • Roma

The clinical management of AML: Updates from ASH
Naval Daver • Houston

IDH case presentation
Adolfo de la Fuente • Madrid

Discussion

10.00 SESSION VI

CHALLENGES IN MYELODISPLASTIC SYNDROMES
Chairmen: Maria Teresa Voso, Uwe Platzbecker

10.00 Targeting inflammation in lower-risk MDS
Anne-Sophie Kubasch • Leipzig

10.20 Lower-risk MDS
Uwe Platzbecker • Leipzig

10.50 Higher-risk MDS
Naval Daver • Houston

11.10 Is it possible to stop therapy in MDS?
Pellegrino Musto • Bari

11.30 Discussion

11.40 – 12.20 SOHO ITALY LECTURES

Introduced by Alessandro Isidori (Congress Chair), Giovanni Martinelli and Claudio Cerchione • SOHO Italy Presidents

11.40 Lecture (pre-recorded)- Venetoclax-based combination in newly diagnosed acute myeloid leukemia: a new golden standard?
Courtney Di Nardo • Houston

12.00 Lecture – Immunotherapy in AML and MDS
Naval Daver • Houston

12.20 SOHO LECTURES Live Q&A
Chaired by Alessandro Isidori, Giovanni Martinelli, Claudio Cerchione

12.30 – 13.30 Lunch

13.30 SESSION VII

CHALLENGES IN ACUTE MYELOID LEUKEMIA

Chairmen: Alessandro Isidori, Adolfo de la Fuente Burguera

13.30 Emerging targeted therapies and combinations
Adolfo de la Fuente Burguera • Madrid

13.50 Current treatment of high-risk AML
Alessandro Isidori • Pesaro

14.10 Front-line treatment in the elderly
Felicitto Ferrara • Naples

14.30 Minimal residual disease: how does it guide our treatment choices?
Adriano Venditti • Rome

14.50 Maintenance therapy
Giuseppe Visani • Pesaro

15.10 Treatment of resistant-refractory disease
Naval Daver • Houston

15.30 Discussion and learning test

provider n. 2773



www.proeventi.it
info@proeventi.it

CME INFO & REGISTRATION

Event n. 2773 - 366183

14 CME Credits for : Hematologists and Biologists

Free registration: www.proeventi.it

pin : current

Objective N. 3

Clinical documentation.

Clinical-assistance pathways diagnostics and rehabilitation, care profiles - care profiles

With the unrestricted educational grant of

DIAMOND

abbvie

SERVIER
moved by you

Janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

SILVER



BRONZE

AstraZeneca

NOVARTIS



sanofi

GSK



Jazz Pharmaceuticals

VIATRIS